Halma plc account plan
Innovative safety and health technologies
At a glance
FTSE 100 group of life-saving technology companies in safety, environmental analysis and healthcare, with FY2026 revenue of £2,582.3m.
Halma plc is a FTSE 100 group of "life-saving technology companies" that acquires small to medium-sized businesses in safety, environmental and healthcare niches and grows them under a decentralised model in which each company keeps its brand and board. It operates in more than 20 countries and sells to customers in over 100 countries, from small businesses to OEMs, with the US its largest market at 48% of revenue. In FY2026 (year to 31 March 2026) revenue rose 14.9% to £2,582.3m, with organic growth of 16.6%, and Adjusted EBIT rose 22.2% to £594.5m at a 23.0% margin, its 23rd consecutive year of record Adjusted profit. It has over 9,000 employees and is listed on the London Stock Exchange (LON: HLMA).
Business units
Environmental & Analysis
40% of FY2026 Group revenue (£1,037.7m)Optical Solutions (including Avo Photonics' optical switches for a hyperscaler customer), Water Analysis & Treatment and Environmental Monitoring & Measurement for water utilities, gas analysis, data connectivity and infrastructure inspection. FY2026 revenue rose 33.6% (organic +35.7%) with Adjusted profit of £250.6m; the US is 68% of sector revenue. Steve Brown becomes Sector Chief Executive from 1 September 2026, succeeding Constance Baroudel.
Safety
37% of FY2026 Group revenue (£947.5m)Fire Safety, Public Safety, Worker Safety and Infrastructure & Asset Safety for construction, energy, utilities, transportation and manufacturing, with brands such as Apollo Fire Detectors, Ampac, BEA and Crowcon. FY2026 revenue rose 5.0% (organic +6.5%) and the margin reached a record 26.8%; E2S and Safetec were acquired. Led by Funmi Adegoke, Sector Chief Executive.
Healthcare
23% of FY2026 Group revenue (£598.4m)Eye health diagnostics and surgery, vital signs monitoring, minimally invasive instruments, surgical devices, women's health, healthcare asset tracking and fluidic components; the US is 52% of sector revenue. FY2026 revenue rose 4.9% (organic +6.3%) with a 23.9% margin, and recent deals (Surgistar, Dreampath Diagnostics, Näslund Medical, itemedical) add diagnostics and clinical data. Bill Stoval becomes Healthcare Sector Chief Executive.
Strategic priorities
- Double earnings every five years
- Halma aspires to double earnings every five years while keeping high returns; KPIs include organic revenue and profit growth of at least 5%, Adjusted EPS growth of at least 10% and an Adjusted EBIT margin of 19% to 23%.
- Acquisitions of niche companies
- A record £447m was spent on five acquisitions in FY2026 and a record £515m on six in FY2027 to 24 September 2026, with a healthy pipeline across all three sectors.
- Organic investment in R&D
- Investing in organic growth is the "number one capital allocation priority": R&D was £122.6m (4.7% of revenue) and capex £56.2m in FY2026.
- Scale photonics and diversify
- Photonics growth of about 30% is guided for FY2027; management says the constraint is resource rather than capacity, and it is looking at other opportunities to diversify away from the single hyperscaler customer.
- Talent and portfolio discipline
- Nearly 300 leaders are in development programmes, and Halma will "selectively divest" businesses that no longer fit, such as AAI, Labsphere, Cardios and NovaBone.
Latest results
In its trading update of 24 September 2026, ahead of the half year to 30 September 2026, Halma reported "strong progress in the first half" with broad-based growth and order intake ahead of revenue and of the prior year. It confirmed FY2027 guidance for low double-digit organic constant currency revenue growth, including about five percentage points of photonics premium, and raised Adjusted EBIT margin guidance to 23.5%-24% from around 22.7%. Stronger Sterling is expected to cut FY2027 revenue by about £8m and profit by about £2m. In the prior half year to 30 September 2025, revenue had risen 15.2% to £1,237.4m.
Investments and deals
- FY2026 acquisitions
- E2S for £226m (its largest ever, December 2025), Brownline for €146m, Safetec for €74m and two healthcare bolt-ons, for £447m in total.
- FY2027 acquisitions
- Dreampath Diagnostics (€279m), Pyxis water quality monitoring ($200m), Näslund Medical ($45m), itemedical (€23m), Surgistar (US$90m) and DCR Inspection Systems, for a record £515m.
- Disposals
- Three disposals realised about £83m, including Labsphere, Cardios and NovaBone for $56m in August 2026.
- R&D and capex
- Organic investment of £179m in FY2026 (R&D £122.6m, capex £56.2m), with FY2027 capex guided at £55m to £60m.
Challenges and risks
- Customer concentration in photonics
- One hyperscaler customer was 20% of Group revenue in FY2026, under a PO-based relationship with six to twelve months of visibility and no contract.
- Economic and geopolitical uncertainty
- Halma cites continued economic, geopolitical and market uncertainty, US project delays in Fire Safety and Infrastructure & Asset Safety, and supply chain, inflation and currency effects.
- Cyber and IT interruption
- Cyber is a "top priority" for the Board, and emerging risks include the pace of AI-driven change and tighter data and AI regulation.
- Scaling resources for photonics
- Management says the photonics limit is "probably more on the resource front" and requires an entire supply ecosystem to keep scaling.
- Acquisition integration
- Acquisitions and Portfolio Management is a principal risk as deal volume reaches record levels, with more spending on M&A integration.
What leadership says
“Our Sustainable Growth Model enables us to invest with confidence and deliver compounding growth over the long term.”
“our objective is to continue our track record of compounding at a double-digit rate over the long term”
“This balanced performance combined with over £600m of investment underpins our ability to deliver sustained compounding growth and strong returns over the long term.”
“It's PO-based, we've got sort of six to twelve months of visibility, but fundamentally, there's not a contract in place”
Where a supplier can help
- Photonics supply chain and talent
- The photonics scaling priority is resource-constrained, opening doors for component suppliers, contract manufacturing, engineering recruitment and supply chain partners.
- M&A sourcing and integration
- Record acquisition activity and added M&A teams create demand for deal sourcing data, due diligence and post-merger integration services.
- Group cyber and AI capabilities
- Central spending on cyber security and AI, and the Board's cyber priority, suit security and AI vendors able to serve a decentralised group of companies.
- R&D tooling for operating companies
- Bottom-up R&D of £122.6m across many companies is an opening for engineering software, testing and product development services sold company by company.
- Healthcare diagnostics and clinical data
- New diagnostics and clinical data acquisitions such as Dreampath and itemedical create needs for integration, interoperability and regulatory support.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Halma plc?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Halma plc Annual Report and Accounts 2026 (year to 31 March 2026)
- Halma is a FTSE 100 group of "life-saving technology companies" organised in three sectors: Environmental & Analysis (£1,037.7m, 40% of revenue), Safety (£947.5m, 37%) and Healthcare (£598.4m, 23%); over 9,000 employees, customers in more than 100 countries.
- FY2026 (year to 31 March 2026): revenue +14.9% to £2,582.3m, organic growth 16.6%; Adjusted EBIT +22.2% to £594.5m at a 23.0% margin; Adjusted EPS +21.0% to 114.05p; 23rd consecutive year of record Adjusted profit.
- Photonics premium: one long-standing "hyperscaler" customer of Avo Photonics (co-design and manufacture of optical switches) was 20% of Group revenue (2025: 15%), about half of E&A revenue, growing 52%; it added about eight percentage points to organic growth.
- The US is 48% of revenue (£1,237.1m, organic +26.2%); Mainland Europe 19%, UK 13%, Asia Pacific 13%.
- Record M&A: £447m for five companies (E2S for £226m, its largest ever; Brownline €146m; Safetec €74m; two healthcare bolt-ons); after year end Surgistar (US$90m) and DCR, and disposals of Labsphere and Cardios.
- Organic investment of £179m: R&D £122.6m (4.7% of revenue) and capex £56.2m; net debt £769.1m, 1.16x Adjusted EBITDA; ROTIC 16.2% vs WACC 10.2%.
- FY2027 outlook: low double-digit organic constant currency revenue growth including about 5 points of photonics premium (photonics growth of about 30%); Adjusted EBIT margin in line with FY2026 excluding the Nuvonic one-off.
- Leadership changes: Constance Baroudel (E&A) leaves to become CEO of Spectris; Steve Brown moves to E&A from 1 September 2026, Bill Stoval becomes Healthcare Sector Chief Executive; CTO Catherine Michel leaves end of June.
- Halma plc Trading update, 24 September 2026
- Trading update of 24 September 2026, ahead of the half year to 30 September 2026: "strong progress in the first half" with broad-based growth.
- FY2027 guidance confirmed for low double-digit organic constant currency revenue growth, including about five percentage points of photonics premium (photonics growth of about 30%).
- Adjusted EBIT margin guidance raised to 23.5%-24% for FY2027, from around 22.7% previously, on operational delivery and product and portfolio mix in all three sectors.
- Order intake remains ahead of revenue year to date and of the same period last year.
- Six acquisitions year to date for a record £515m, including Dreampath Diagnostics (€279m), Pyxis water quality monitoring ($200m), Näslund Medical ($45m) and itemedical (€23m).
- Three disposals realised about £83m, including NovaBone for $56m in August 2026.
- Stronger Sterling: about £8m negative revenue effect and £2m negative profit effect expected for FY2027 at current rates.
- Half year results due on 19 November 2026.
- Halma plc Half Year Results 2025/26 (six months to 30 September 2025)
- Half year to 30 September 2025 (published 20 November 2025): revenue +15.2% to £1,237.4m, organic +17.6% (+16.7% excluding the Nuvonic one-off).
- Adjusted EBIT +26.7% to £282.0m; excluding the one-off +22.8% to £273.4m with margin 22.3% (+160bps); Adjusted EPS +28.6% to 55.32p.
- Photonics premium was about half of organic growth; the "hyperscaler" customer was 19% of Group revenue (H1 2024/25: 14%).
- By sector: Environmental & Analysis revenue +35.3% (organic +38.9%), Safety +4.1% with a record 27.0% margin, Healthcare +6.6% on a steady market recovery.
- US revenue +20.1% (organic +25.9%), 48% of Group revenue.
- Investment: R&D £59.1m (4.8% of revenue); Brownline bought for €150m; AAI sold for £10m; cash conversion 79%, net debt £640.6m (1.03x EBITDA).
- FY2026 guidance raised to mid-teens organic constant currency revenue growth and an Adjusted EBIT margin of around 22%; interim dividend +7% to 9.63p.
- Halma Full Year Results 2025/26: summary of analysts' presentation with Q&A
- Full year 2025/26 results presentation and Q&A, 11 June 2026, by Group Chief Executive Marc Ronchetti and CFO Carole Cran.
- Organic revenue up 16.2% and EBIT up 19% (excluding the Nuvonic one-off); photonics was about half of growth; a record £475m spent on acquisitions and £123m on R&D.
- Photonics: about 30% growth guided for FY27, "a further £160 million of revenue over the next 12 months, [from] over £500 million", a three-year CAGR of about 40%; the constraint is "probably more on the resource front", not capacity.
- Ronchetti will not read across from hyperscaler capex: guidance is based on 6 to 12 months of visibility; "there will always be technology choices in fast growing markets".
- Outside photonics, Cran points to the 5% organic target and 7.5% ambition as the "sensible place" for each sector; margins to stay flat for reinvestment.
- Portfolio: "Would I buy this business today?" drives disposals (AAI, Labsphere, Cardios); no uptick in divestments expected.
- Growth ambition: "our objective is to continue our track record of compounding at a double-digit rate over the long term".
- Halma Half Year Results 2025/26: summary of analysts' presentation with Q&A
- Half year 2025/26 results presentation and Q&A, 20 November 2025, by Group Chief Executive Marc Ronchetti and CFO Carole Cran.
- Results: headline revenue +15%, EBIT +27%; margin 22.3% excluding the one-off; about £300m invested in the half; guidance raised for the second time in the year.
- Theme: combining "a long term view with short term agility" ("Yes, and..."): Crowcon in battery energy storage, Sentric in data centres, Alicat across fast-growing markets.
- Photonics: Avo Photonics had about £4 million of revenue when bought in 2011; the hyperscaler relationship is "PO-based" with six to twelve months of visibility and no contract; Halma looks to diversify but will keep the relationship.
- M&A: growing 7.5% a year by acquisition on about half a billion means buying about £40 million of profit next year; more confidence to do larger deals such as Brownline.
- Healthcare: "through the destocking, but we're not at the stage I'd want to say we're back to normal levels of demand"; margins to move back towards historic levels progressively.
- Central costs run at about 2% of revenue, with more spent on M&A integration, AI and cyber security.
Questions about Halma plc
What does Halma do?
Halma is a group of life-saving technology companies in three sectors: Environmental & Analysis, Safety and Healthcare. It acquires companies in specialist niches and grows them with a decentralised model.
What is Halma's revenue?
FY2026 (year to 31 March 2026) revenue was £2,582.3m, up 14.9%, with Adjusted EBIT of £594.5m.
How many employees does Halma have?
Halma has over 9,000 employees in more than 20 countries.
Who leads Halma?
Marc Ronchetti has been Group Chief Executive since April 2023, Carole Cran is CFO since April 2025, and Dame Louise Makin is Chair.
What is Halma's strategy?
Halma aims to double earnings every five years by investing in organic growth, acquiring purpose-aligned small to medium-sized companies and paying a progressive dividend.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)